Literature DB >> 26707978

Stabilization of HIF-1α by FG-4592 promotes functional recovery and neural protection in experimental spinal cord injury.

Kai Wu1, Kailiang Zhou1, Yongli Wang1, Yifei Zhou1, Naifeng Tian1, Yaosen Wu1, Deheng Chen1, Di Zhang1, Xiangyang Wang1, Huazi Xu2, Xiaolei Zhang3.   

Abstract

Previous studies have shown that inhibition of prolyl hydroxylase(PHD) stabilizes Hypoxia-inducible factor 1, alpha subunit(HIF-1α), increases tolerance to hypoxia, and improves the prognosis of many diseases. However, the role of PHD inhibitor (PHDI) in the recovery of spinal cord injury remains controversial. In this study, we investigated the protective role of a novel PHDI FG-4592 both in vivo and in vitro. FG-4592 treatment stabilized HIF1α expression both in PC12 cells and in spinal cord. FG-4592 treatment significantly inhibited tert-Butyl hydroperoxide(TBHP)-induced apoptosis and increases the survival of neuronal PC-12 cells. FG-4592 administration also improved recovery and increased the survival of neurons in spinal cord lesions in the mice model. Combination therapy including the specific HIF-1α blocker YC-1 down-regulated the HIF-1α expression and partially abolished the protective effect of FG-4592. Taken together, our results revealed that the role of FG-4592 in SCI recovery is related to the stabilization of HIF-1α and inhibition of apoptosis. Overall, our study suggests that PHDIs may be feasible candidates for therapeutic intervention after SCI and central nervous system disorders in humans.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Apoptosis; HIF1α; Prolyl hydroxylase inhibitor; Spinal cord injury

Mesh:

Substances:

Year:  2015        PMID: 26707978     DOI: 10.1016/j.brainres.2015.12.017

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  21 in total

Review 1.  Unlocking mammalian regeneration through hypoxia inducible factor one alpha signaling.

Authors:  Kelsey G DeFrates; Daniela Franco; Ellen Heber-Katz; Phillip B Messersmith
Journal:  Biomaterials       Date:  2021-01-09       Impact factor: 12.479

2.  QSAR modeling and in silico design of small-molecule inhibitors targeting the interaction between E3 ligase VHL and HIF-1α.

Authors:  Jing Pan; Yanmin Zhang; Ting Ran; Anyang Xu; Xin Qiao; Lingfeng Yin; Weineng Zhou; Lu Zhu; Junnan Zhao; Tao Lu; Yadong Chen; Yulei Jiang
Journal:  Mol Divers       Date:  2017-07-08       Impact factor: 2.943

3.  Roxadustat alleviates nitroglycerin-induced migraine in mice by regulating HIF-1α/NF-κB/inflammation pathway.

Authors:  Dai-Gang Yang; Yong-Yao Gao; Ze-Qun Yin; Xue-Rui Wang; Xian-She Meng; Ting-Feng Zou; Ya-Jun Duan; Yuan-Li Chen; Chen-Zhong Liao; Zhou-Ling Xie; Xiao-Dong Fan; Lu Sun; Ji-Hong Han; Xiao-Xiao Yang
Journal:  Acta Pharmacol Sin       Date:  2022-08-10       Impact factor: 7.169

4.  Prostaglandin E1 reduces apoptosis and improves the homing of mesenchymal stem cells in pulmonary arterial hypertension by regulating hypoxia-inducible factor 1 alpha.

Authors:  De-Tian Jiang; Lei Tuo; Xiao Bai; Wei-Dong Bing; Qing-Xi Qu; Xin Zhao; Guang-Min Song; Yan-Wen Bi; Wen-Yu Sun
Journal:  Stem Cell Res Ther       Date:  2022-07-16       Impact factor: 8.079

Review 5.  Oxygen, Metabolism, and Regeneration: Lessons from Mice.

Authors:  Ellen Heber-Katz
Journal:  Trends Mol Med       Date:  2017-10-05       Impact factor: 11.951

6.  Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men.

Authors:  Arezoo Daryadel; Carla Bettoni; Thomas Haider; Pedro H Imenez Silva; Udo Schnitzbauer; Eva Maria Pastor-Arroyo; Roland H Wenger; Max Gassmann; Carsten A Wagner
Journal:  Pflugers Arch       Date:  2018-07-02       Impact factor: 3.657

Review 7.  Neuroinflammation and Microvascular Dysfunction After Experimental Subarachnoid Hemorrhage: Emerging Components of Early Brain Injury Related to Outcome.

Authors:  Joseph R Geraghty; Joseph L Davis; Fernando D Testai
Journal:  Neurocrit Care       Date:  2019-10       Impact factor: 3.210

8.  Roxadustat (FG-4592) Facilitates Recovery From Renal Damage by Ameliorating Mitochondrial Dysfunction Induced by Folic Acid.

Authors:  Xue Li; Bo Jiang; Yu Zou; Jie Zhang; Yuan-Yuan Fu; Xiao-Yue Zhai
Journal:  Front Pharmacol       Date:  2022-02-25       Impact factor: 5.810

9.  Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298).

Authors:  Pedro Soares; Morgan S Gadd; Julianty Frost; Carles Galdeano; Lucy Ellis; Ola Epemolu; Sonia Rocha; Kevin D Read; Alessio Ciulli
Journal:  J Med Chem       Date:  2017-09-18       Impact factor: 7.446

10.  Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson's Diseases in Vitro and in Vivo: Regulation of Redox Biology and Mitochondrial Function.

Authors:  Xuan Li; Xin-Xin Cui; Ya-Jing Chen; Ting-Ting Wu; Huaxi Xu; Huiyong Yin; Yun-Cheng Wu
Journal:  Front Aging Neurosci       Date:  2018-04-27       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.